MARKET

BMRN

BMRN

BioMarin Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

75.00
+0.79
+1.06%
After Hours: 75.00 0 0.00% 17:07 09/17 EDT
OPEN
74.47
PREV CLOSE
74.21
HIGH
75.19
LOW
72.70
VOLUME
993.49K
TURNOVER
--
52 WEEK HIGH
106.74
52 WEEK LOW
70.82
MARKET CAP
13.46B
P/E (TTM)
-121.4575
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BMRN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 23 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

BMRN News

  • Stocks That Fell to 3-Year Lows in the Week of Sept. 13
  • GuruFocus.com.2d ago
  • BioMarin Pharmaceutical (BMRN) Presents At Morgan Stanley 17th Annual Global Healthcare Conference - Slideshow
  • Seeking Alpha - Article.4d ago
  • Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Overpaying Its CEO?
  • Simply Wall St..4d ago
  • BioMarin to Participate in Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York
  • PR Newswire.09/09 21:05

More

Industry

Pharmaceuticals
+0.65%
Pharmaceuticals & Medical Research
+0.57%

Hot Stocks

Name
Price
%Change

About BMRN

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.
More

Webull offers BioMarin Pharmaceutical Inc. (BMRN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.